Neues in der Behandlung intrakranieller Blutungen

D. Staykov

doi:10.1055/s-0034-1394384

Aktuelle Neurologie, Table of Contents

Aktuelle Neurologie 2014; 41(09): 502-508
DOI: 10.1055/s-0034-1394384

Neues in der Neurologie

Neues in der Behandlung intrakranieller Blutungen

What’s New in the Treatment of Intracranial Hemorrhage

D. Staykov

¹Neurologische Klinik mit Poliklinik, Universitätsklinikum Erlangen

› Author Affiliations

Abstract

Zusammenfassung

Die vorliegende Übersicht befasst sich mit den Ergebnissen ausgewählter größerer Studien zur Behandlung intrakranieller Blutungen aus den vergangenen 2 Jahren. Neben dem Blutdruckmanagement und der operativen Behandlung intrazerebraler Blutungen, werden Studien zu verschiedenen medikamentösen Strategien zur Prävention von vasospasmusassoziierter Morbidität nach Subarachnoidalblutung zusammengefasst.

Abstract

The present article reviews recent research dealing with the treatment of intracranial hemorrhage. Several newly published larger clinical trials are summarized, including topics as blood pressure management after intracerebral hemorrhage, surgery for spontaneous intracerebral hemorrhage and different medical treatment strategies to prevent vasospasm associated morbidity after subarachnoid hemorrhage.

Schlüsselwörter

intrakranielle Blutung - intrazerebrale Blutung - Subarachnoidalblutung

Keywords

intracranial hemorrhage - intracerebral hemorrhage - subarachnoid hemorrhage

Full Text

References

Literatur
1 Adeoye O, Broderick JP. Advances in the management of intracerebral hemorrhage. Nat Rev Neurol 2010; 6: 593-601
2 van Asch CJ, Luitse MJ, Rinkel GJ et al. Incidence, case fatality, and functional outcome of intracerebral haemorrhage over time, according to age, sex, and ethnic origin: a systematic review and meta-analysis. Lancet Neurol 2010; 9: 167-176
3 Brott T, Thalinger K, Hertzberg V. Hypertension as a risk factor for spontaneous intracerebral hemorrhage. Stroke 1986; 17: 1078-1083
4 Thrift AG, Donnan GA, McNeil JJ. Epidemiology of intracerebral hemorrhage. Epidemiol Rev 1995; 17: 361-381
5 Flaherty ML. Anticoagulant-associated intracerebral hemorrhage. Semin Neurol 2010; 30: 565-572
6 Staykov D, Huttner HB, Kohrmann M et al. Novel approaches to the treatment of intracerebral haemorrhage. Int J Stroke 2010; 5: 457-465
7 Chin JH, Vora N. The global burden of neurologic diseases. Neurology 2014; 83: 349-351
8 Broderick JP, Brott TG, Duldner JE et al. Volume of intracerebral hemorrhage. A powerful and easy-to-use predictor of 30-day mortality. Stroke 1993; 24: 987-993
9 Daverat P, Castel JP, Dartigues JF et al. Death and functional outcome after spontaneous intracerebral hemorrhage. A prospective study of 166 cases using multivariate analysis. Stroke 1991; 22: 1-6
10 Tuhrim S, Horowitz DR, Sacher M et al. Validation and comparison of models predicting survival following intracerebral hemorrhage. Crit Care Med 1995; 23: 950-954
11 Davis SM, Broderick J, Hennerici M et al. Hematoma growth is a determinant of mortality and poor outcome after intracerebral hemorrhage. Neurology 2006; 66: 1175-1181
12 Steiner T, Diringer MN, Schneider D et al. Dynamics of intraventricular hemorrhage in patients with spontaneous intracerebral hemorrhage: risk factors, clinical impact, and effect of hemostatic therapy with recombinant activated factor VII. Neurosurgery. 2006; 59: 767-773 discussion 773–764
13 Diringer MN, Edwards DF, Zazulia AR. Hydrocephalus: a previously unrecognized predictor of poor outcome from supratentorial intracerebral hemorrhage. Stroke 1998; 29: 1352-1357
14 Keep RF, Hua Y, Xi G. Intracerebral haemorrhage: mechanisms of injury and therapeutic targets. Lancet Neurol 2012; 11: 720-731
15 Morgenstern LB, Hemphill 3rd JC, Anderson C et al. Guidelines for the Management of Spontaneous Intracerebral Hemorrhage. A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke 2010; 41: 2108-2129
16 Diener HC, Weimar C. Leitlinien für Diagnostik und Therapie in der Neurologie. 5^th. Aufl Thieme Verlag; 2012
17 Prabhakaran S, Naidech AM. Ischemic brain injury after intracerebral hemorrhage: a critical review. Stroke 2012; 43: 2258-2263
18 Kim-Han JS, Kopp SJ, Dugan LL et al. Perihematomal mitochondrial dysfunction after intracerebral hemorrhage. Stroke 2006; 37: 2457-2462
19 Powers WJ, Zazulia AR, Videen TO et al. Autoregulation of cerebral blood flow surrounding acute (6–22 hours) intracerebral hemorrhage. Neurology 2001; 57: 18-24
20 Anderson CS, Huang Y, Wang JG et al. Intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT): a randomised pilot trial. Lancet Neurol 2008; 7: 391-399
21 Anderson CS, Heeley E, Huang Y et al. Rapid Blood-Pressure Lowering in Patients with Acute Intracerebral Hemorrhage. N Engl J Med 2013; 368: 2355-2365
22 Manning L, Hirakawa Y, Arima H et al. Blood pressure variability and outcome after acute intracerebral haemorrhage: a post-hoc analysis of INTERACT2, a randomised controlled trial. Lancet Neurol 2014; 13: 364-373
23 Steiner T, Al-Shahi Salman R, Beer R et al. European Stroke Organisation (ESO) guidelines for the management of spontaneous intracerebral hemorrhage. Int J Stroke 2014; 9: 840-855
24 Mendelow AD, Gregson BA, Fernandes HM et al. Early surgery versus initial conservative treatment in patients with spontaneous supratentorial intracerebral haematomas in the International Surgical Trial in Intracerebral Haemorrhage (STICH): a randomised trial. Lancet 2005; 365: 387-397
25 Mendelow AD, Gregson BA, Rowan EN et al. Early surgery versus initial conservative treatment in patients with spontaneous supratentorial lobar intracerebral haematomas (STICH II): a randomised trial. Lancet 2013; 382: 397-408
26 Hattori N, Katayama Y, Maya Y et al. Impact of stereotactic hematoma evacuation on activities of daily living during the chronic period following spontaneous putaminal hemorrhage: a randomized study. J Neurosurg 2004; 101: 417-420
27 Wang WZ, Jiang B, Liu HM et al. Minimally invasive craniopuncture therapy vs. conservative treatment for spontaneous intracerebral hemorrhage: results from a randomized clinical trial in China. Int J Stroke 2009; 4: 11-16
28 Chen X, Chen W, Ma A et al. Frameless stereotactic aspiration and subsequent fibrinolytic therapy for the treatment of spontaneous intracerebral haemorrhage. Br J Neurosurg 2011; 25: 369-375
29 Gaab MR. Intracerebral hemorrhage (ICH) and intraventricular hemorrhage (IVH): improvement of bad prognosis by minimally invasive neurosurgery. World Neurosurg 2011; 75: 206-208
30 Kuo LT, Chen CM, Li CH et al. Early endoscope-assisted hematoma evacuation in patients with supratentorial intracerebral hemorrhage: case selection, surgical technique, and long-term results. Neurosurg Focus 2011; 30: E9
31 Lin HL, Lo YC, Liu YF et al. Endoscopic evacuation of hypertensive putaminal hemorrhage guided by the 3D reconstructed CT scan: a preliminary report. Clin Neurol Neurosurg 2010; 112: 892-896
32 Hanley DF. MISTIE II Trial: 365-day Results Demonstrate Improved Outcomes and Cost Benefit. International Stroke Conference; 6.–8. February 2013. 2013. Honolulu, Hawaii, USA:
33 Mould WA, Carhuapoma JR, Muschelli J et al. Minimally Invasive Surgery Plus Recombinant Tissue-type Plasminogen Activator for Intracerebral Hemorrhage Evacuation Decreases Perihematomal Edema. Stroke 2013; 44: 627-634
34 Nieuwkamp DJ, Setz LE, Algra A et al. Changes in case fatality of aneurysmal subarachnoid haemorrhage over time, according to age, sex, and region: a meta-analysis. Lancet Neurol 2009; 8: 635-642
35 Lovelock CE, Rinkel GJ, Rothwell PM. Time trends in outcome of subarachnoid hemorrhage: Population-based study and systematic review. Neurology 74: 1494-1501
36 Bederson JB, Connolly Jr ES, Batjer HH et al. Guidelines for the management of aneurysmal subarachnoid hemorrhage: a statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. Stroke 2009; 40: 994-1025
37 Feigin VL, Rinkel GJ, Lawes CM et al. Risk factors for subarachnoid hemorrhage: an updated systematic review of epidemiological studies. Stroke 2005; 36: 2773-2780
38 Rabinstein AA, Lanzino G, Wijdicks EF. Multidisciplinary management and emerging therapeutic strategies in aneurysmal subarachnoid haemorrhage. Lancet Neurol 9: 504-519
39 van Gijn J, Kerr RS, Rinkel GJ. Subarachnoid haemorrhage. Lancet 2007; 369: 306-318
40 van Gijn J, Rinkel GJ. Subarachnoid haemorrhage: diagnosis, causes and management. Brain 2001; 124: 249-278
41 Fisher CM, Kistler JP, Davis JM. Relation of cerebral vasospasm to subarachnoid hemorrhage visualized by computerized tomographic scanning. Neurosurgery 1980; 6: 1-9
42 Pham M, Johnson A, Bartsch AJ et al. CT perfusion predicts secondary cerebral infarction after aneurysmal subarachnoid hemorrhage. Neurology 2007; 69: 762-765
43 Fontanarosa PB. Recognition of subarachnoid hemorrhage. Ann Emerg Med 1989; 18: 1199-1205
44 Fisher CM, Roberson GH, Ojemann RG. Cerebral vasospasm with ruptured saccular aneurysm – the clinical manifestations. Neurosurgery 1977; 1: 245-248
45 Chaichana KL, Pradilla G, Huang J et al. Role of inflammation (leukocyte-endothelial cell interactions) in vasospasm after subarachnoid hemorrhage. World Neurosurg 2010; 73: 22-41
46 Dreier JP, Major S, Manning A et al. Cortical spreading ischaemia is a novel process involved in ischaemic damage in patients with aneurysmal subarachnoid haemorrhage. Brain 2009; 132: 1866-1881
47 Macdonald RL, Higashida RT, Keller E et al. Clazosentan, an endothelin receptor antagonist, in patients with aneurysmal subarachnoid haemorrhage undergoing surgical clipping: a randomised, double-blind, placebo-controlled phase 3 trial (CONSCIOUS-2). Lancet Neurol 2011; 10: 618-625
48 Macdonald RL, Higashida RT, Keller E et al. Randomized trial of clazosentan in patients with aneurysmal subarachnoid hemorrhage undergoing endovascular coiling. Stroke 2012; 43: 1463-1469
49 Dorhout Mees SM, Algra A, Vandertop WP et al. Magnesium for aneurysmal subarachnoid haemorrhage (MASH-2): a randomised placebo-controlled trial. Lancet 2012; 380: 44-49
50 Kirkpatrick PJ, Turner CL, Smith C et al. Simvastatin in aneurysmal subarachnoid haemorrhage (STASH): a multicentre randomised phase 3 trial. Lancet Neurol 2014; 13: 666-675
51 Roux S, Breu V, Giller T et al. Ro 61-1790, a new hydrosoluble endothelin antagonist: general pharmacology and effects on experimental cerebral vasospasm. J Pharmacol Exp Ther 1997; 283: 1110-1118
52 Macdonald RL, Kassell NF, Mayer S et al. Clazosentan to overcome neurological ischemia and infarction occurring after subarachnoid hemorrhage (CONSCIOUS-1): randomized, double-blind, placebo-controlled phase 2 dose-finding trial. Stroke 2008; 39: 3015-3021
53 Vergouwen MD, Algra A, Rinkel GJ. Endothelin receptor antagonists for aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis update. Stroke 2012; 43: 2671-2676
54 van den Bergh WM, Algra A, van Kooten F et al. Magnesium sulfate in aneurysmal subarachnoid hemorrhage: a randomized controlled trial. Stroke 2005; 36: 1011-1015